as 07-26-2024 4:00pm EST
Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its main product in clinical development is bremelanotide, which treats hypoactive sexual desire disorder, which is a type of female sexual dysfunction.
Founded: | 1986 | Country: | United States |
Employees: | N/A | City: | CRANBURY |
Market Cap: | 27.9M | IPO Year: | 1993 |
Target Price: | $17.00 | AVG Volume (30 days): | 86.8K |
Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -2.51 | EPS Growth: | N/A |
52 Week Low/High: | $1.43 - $5.65 | Next Earning Date: | 05-15-2024 |
Revenue: | $5,902,023 | Revenue Growth: | 52.80% |
Revenue Growth (this year): | -14.13% | Revenue Growth (next year): | 27.23% |
Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
DEVEER ROBERT K JR | PTN | Director | Apr 11 '24 | Buy | $2.12 | 6,000 | $12,703.20 | 40,845 | SEC Form 4 |
DEVEER ROBERT K JR | PTN | Director | Mar 6 '24 | Sell | $2.00 | 1,685 | $3,370.00 | 44,860 | SEC Form 4 |
DEVEER ROBERT K JR | PTN | Director | Mar 6 '24 | Sell | $2.00 | 7,286 | $14,572.73 | 37,574 | SEC Form 4 |
DEVEER ROBERT K JR | PTN | Director | Mar 6 '24 | Sell | $2.00 | 200 | $400.00 | 37,574 | SEC Form 4 |
DEVEER ROBERT K JR | PTN | Director | Mar 6 '24 | Sell | $2.01 | 1,808 | $3,634.08 | 35,566 | SEC Form 4 |
DEVEER ROBERT K JR | PTN | Director | Mar 6 '24 | Sell | $2.01 | 106 | $213.06 | 35,460 | SEC Form 4 |
DEVEER ROBERT K JR | PTN | Director | Mar 6 '24 | Sell | $2.02 | 460 | $929.20 | 35,000 | SEC Form 4 |
DEVEER ROBERT K JR | PTN | Director | Mar 6 '24 | Sell | $2.03 | 155 | $314.65 | 34,845 | SEC Form 4 |
WILLS STEPHEN T | PTN | Executive VP and CFO/COO | Dec 6 '23 | Sell | $2.42 | 2,807 | $6,778.91 | 329,713 | SEC Form 4 |
WILLS STEPHEN T | PTN | Executive VP and CFO/COO | Dec 6 '23 | Sell | $2.64 | 2,191 | $5,784.24 | 327,522 | SEC Form 4 |
DUNTON ALAN W | PTN | Director | Dec 4 '23 | Sell | $2.48 | 199 | $493.52 | 45,075 | SEC Form 4 |
DUNTON ALAN W | PTN | Director | Dec 4 '23 | Sell | $2.46 | 1 | $2.46 | 45,074 | SEC Form 4 |
PTN Breaking Stock News: Dive into PTN Ticker-Specific Updates for Smart Investing
PR Newswire
a month ago
Clinical Trials Arena
a month ago
PR Newswire
a month ago
Clinical Trials Arena
a month ago
MT Newswires
a month ago
PR Newswire
a month ago
CNW Group
2 months ago
Simply Wall St.
2 months ago
The information presented on this page, "PTN Palatin Technologies Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.